标题
Emerging Bcl-2 inhibitors for the treatment of cancer
作者
关键词
-
出版物
EXPERT OPINION ON EMERGING DRUGS
Volume 16, Issue 1, Pages 59-70
出版商
Informa Healthcare
发表日期
2010-09-03
DOI
10.1517/14728214.2010.515210
参考文献
相关参考文献
注意:仅列出部分参考文献,下载原文获取全部文献信息。- From sentencing to execution – the processes of apoptosis
- (2015) Kelly L. Moffitt et al. JOURNAL OF PHARMACY AND PHARMACOLOGY
- Exploring death receptor pathways as selective targets in cancer therapy
- (2010) Maria Russo et al. BIOCHEMICAL PHARMACOLOGY
- The BH3-mimetic GX15-070 induces autophagy, potentiates the cytotoxicity of carboplatin and 5-fluorouracil in esophageal carcinoma cells
- (2010) Jingxuan Pan et al. CANCER LETTERS
- Targeting the Bcl-2
- (2010) Mehul P Patel et al. CURRENT OPINION IN ONCOLOGY
- Mitochondria in cell death
- (2010) Melissa J. Parsons et al. Essays in Biochemistry
- The Bcl-2 Homology Domain 3 Mimetic Gossypol Induces Both Beclin 1-dependent and Beclin 1-independent Cytoprotective Autophagy in Cancer Cells
- (2010) Ping Gao et al. JOURNAL OF BIOLOGICAL CHEMISTRY
- The Pan-Bcl-2 Inhibitor (-)-Gossypol Triggers Autophagic Cell Death in Malignant Glioma
- (2010) V. Voss et al. MOLECULAR CANCER RESEARCH
- ABT-737 Overcomes Resistance to Immunotoxin-Mediated Apoptosis and Enhances the Delivery of Pseudomonas Exotoxin-Based Proteins to the Cell Cytosol
- (2010) R. Traini et al. MOLECULAR CANCER THERAPEUTICS
- Identification of Expression Signatures Predictive of Sensitivity to the Bcl-2 Family Member Inhibitor ABT-263 in Small Cell Lung Carcinoma and Leukemia/Lymphoma Cell Lines
- (2010) S. K. Tahir et al. MOLECULAR CANCER THERAPEUTICS
- Cancer-selective apoptotic effects of extracellular and intracellular Par-4
- (2010) T Shrestha-Bhattarai et al. ONCOGENE
- G3139 (Genasense) in Patients With Advanced Merkel Cell Carcinoma
- (2009) Manisha H. Shah et al. AMERICAN JOURNAL OF CLINICAL ONCOLOGY-CANCER CLINICAL TRIALS
- The Tumor Suppressor Par-4 Activates an Extrinsic Pathway for Apoptosis
- (2009) Ravshan Burikhanov et al. CELL
- An Open-Label, Multicenter, Phase I/II Study of Single-Agent AT-101 in Men with Castrate-Resistant Prostate Cancer
- (2009) G. Liu et al. CLINICAL CANCER RESEARCH
- SMI of Bcl-2 TW-37 is active across a spectrum of B-cell tumors irrespective of their proliferative and differentiation status
- (2009) Ayad M Al-Katib et al. Journal of Hematology & Oncology
- ApoG2 induces cell cycle arrest of nasopharyngeal carcinoma cells by suppressing the c-Myc signaling pathway
- (2009) Zhe-Yu Hu et al. Journal of Translational Medicine
- Bim-targeted cancer therapy: A link between drug action and underlying molecular changes
- (2009) T. Akiyama et al. MOLECULAR CANCER THERAPEUTICS
- BAD: undertaker by night, candyman by day
- (2009) N N Danial ONCOGENE
- Noxa: at the tip of the balance between life and death
- (2009) C Ploner et al. ONCOGENE
- Bid: a Bax-like BH3 protein
- (2009) L P Billen et al. ONCOGENE
- PUMA, a potent killer with or without p53
- (2009) J Yu et al. ONCOGENE
- CXCR4 nuclear localization follows binding of its ligand SDF-1 and occurs in metastatic but not primary renal cell carcinoma
- (2009) Sun ONCOLOGY REPORTS
- Mechanisms of Antileukemic Activity of the Novel Bcl-2 Homology Domain-3 Mimetic GX15-070 (Obatoclax)
- (2008) M. Konopleva et al. CANCER RESEARCH
- ABT-263: A Potent and Orally Bioavailable Bcl-2 Family Inhibitor
- (2008) C. Tse et al. CANCER RESEARCH
- Alteration of the Mitochondrial Apoptotic Pathway Is Key to Acquired Paclitaxel Resistance and Can Be Reversed by ABT-737
- (2008) O. Kutuk et al. CANCER RESEARCH
- Bcl-2 inhibitors: small molecules with a big impact on cancer therapy
- (2008) M Vogler et al. CELL DEATH AND DIFFERENTIATION
- A Phase I Pharmacokinetic and Pharmacodynamic Correlative Study of the Antisense Bcl-2 Oligonucleotide G3139, in Combination with Carboplatin and Paclitaxel, in Patients with Advanced Solid Tumors
- (2008) G. Liu et al. CLINICAL CANCER RESEARCH
- Phase I/II Study of G3139 (Bcl-2 Antisense Oligonucleotide) in Combination with Doxorubicin and Docetaxel in Breast Cancer
- (2008) S. L. Moulder et al. CLINICAL CANCER RESEARCH
- Targeting the extrinsic apoptosis pathway in cancer
- (2008) Avi Ashkenazi CYTOKINE & GROWTH FACTOR REVIEWS
- Retracted: TW-37, a small-molecule inhibitor of Bcl-2, inhibits cell growth and invasion in pancreatic cancer
- (2008) Zhiwei Wang et al. INTERNATIONAL JOURNAL OF CANCER
- ApoG2, a novel inhibitor of antiapoptotic Bcl-2 family proteins, induces apoptosis and suppresses tumor growth in nasopharyngeal carcinoma xenografts
- (2008) Zhe-Yu Hu et al. INTERNATIONAL JOURNAL OF CANCER
- Tumor resistance to apoptosis
- (2008) Simone Fulda INTERNATIONAL JOURNAL OF CANCER
- ABT-737 Induces Expression of the Death Receptor 5 and Sensitizes Human Cancer Cells to TRAIL-induced Apoptosis
- (2008) Jin H. Song et al. JOURNAL OF BIOLOGICAL CHEMISTRY
- Non-peptidic small molecule inhibitors against Bcl-2 for cancer therapy
- (2008) Asfar S. Azmi et al. JOURNAL OF CELLULAR PHYSIOLOGY
- Randomized Phase II Study of Carboplatin and Etoposide With or Without thebcl-2Antisense Oligonucleotide Oblimersen for Extensive-Stage Small-Cell Lung Cancer: CALGB 30103
- (2008) Charles M. Rudin et al. JOURNAL OF CLINICAL ONCOLOGY
- Discovery of an Orally Bioavailable Small Molecule Inhibitor of Prosurvival B-Cell Lymphoma 2 Proteins
- (2008) Cheol-Min Park et al. JOURNAL OF MEDICINAL CHEMISTRY
- Preclinical studies of Apogossypolone: a new nonpeptidic pan small-molecule inhibitor of Bcl-2, Bcl-XL and Mcl-1 proteins in Follicular Small Cleaved Cell Lymphoma model
- (2008) Alan A Arnold et al. Molecular Cancer
- Critical role of prostate apoptosis response-4 in determining the sensitivity of pancreatic cancer cells to small-molecule inhibitor-induced apoptosis
- (2008) A. S. Azmi et al. MOLECULAR CANCER THERAPEUTICS
- ABT-263 and rapamycin act cooperatively to kill lymphoma cells in vitro and in vivo
- (2008) Scott Ackler et al. MOLECULAR CANCER THERAPEUTICS
- Apoptosis-based treatment of glioblastomas with ABT-737, a novel small molecule inhibitor of Bcl-2 family proteins
- (2008) K E Tagscherer et al. ONCOGENE
- sHA 14-1, a stable and ROS-free antagonist against anti-apoptotic Bcl-2 proteins, bypasses drug resistances and synergizes cancer therapies in human leukemia cell
- (2007) Defeng Tian et al. CANCER LETTERS
Add your recorded webinar
Do you already have a recorded webinar? Grow your audience and get more views by easily listing your recording on Peeref.
Upload NowAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started